ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1567

The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease

Sergio Schwartzman1, Anton Kolomeyer2 and David Chu3, 1Rheumatology, Hospital for Special Surgery, New York, NY, 2Ophthalmology, University of Pittsburgh, Pittsburgh, PA, 3Ophthalmology, Rutgers, Newark, NJ

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: psoriasis, psoriatic arthritis and uveitis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Spondyloarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Psoriatic disease is characterized by the presence of psoriasis with or without an association of extra-dermal manifestations. Inflammatory forms of arthritis are the most common concomitant findings in this continuum but not infrequently other organ systems manifest involvement. There is a dearth of primary literature on autoimmune ocular manifestations in patients with Psoriasis (Ps) and Psoriatic arthritis (PsA) although the prevalence of uveitis in PsA has been documented to be as high as 25.1%. 1

The purpose of this study is to describe the pattern of ocular inflammation in patients with psoriatic disease.

Methods:  Retrospective chart review of ocular manifestations in patients with Ps and PsA from two tertiary care centers in the United States specializing in autoimmune ophthalmic disease.  Data was collected on age, gender, ethnicity, associated autoimmune disease, ocular manifestations, HLA Typing, systemic immunomodulating agents and ocular therapy

Results:

20 patients were identified with the following characteristics:

Age in years at Diagnosis of Ophthalmic Disease mean +/- SD

 45.9 SD +/- 14.4

Male/Female

 5/15

Race

 1 Hispanic, 2 African Americans. 17 Caucasians

Psoriatic Disease

 6 Ps, 14 PsA

Additional Systemic Illnesses

 3 Sarcoid, 2 RA

Pattern of PsA

8 Oligoarticular, 2 Axial, 1 Polyarticular (not available in 3 pts)

Ophthalmic Illness

6 Anterior Uveitis, 3 Panuveitis 2 Scleritis, 1 Episcleritis, 3 Sclerouveitis, 2 PUK, 1 Vasculitis, 1 Multifocal Choroiditis 

Systemic Therapy

Systemic and Local Steroids, Sulfasalzine, Methotrexate, Mycophenolate, Cyclosporin, Adalimumab, Infliximab, Certolizumab, Etanercept, Cytoxan, Rituximab

Number of Patients Requiring More than One Immunomodulatory Medication 

 11

Conclusion:

The breadth and severity of ocular manifestations in patients with Ps and PsA is diverse. This is the largest cohort of patients with autoimmune ophthalmic manifestations and psoriatic disease described to date. There are several unique features of this cohort:

1.  30% of patients had only skin disease. 

2.  Although it appears that anterior uveitis is the most common autoimmune ocular manifestation of this group of diseases in this cohort of patients it tends to be chronic, differentiating this ocular manifestation from the pattern in Ankylosing Spondylitis.

3.  33% of patients had an overlap of two underlying systemic autoimmune diseases.  

4.  When ocular manifestations do occur in patients with psoriatic disease, they tend to be more severe and require more than one immunomodulatory therapy.

5.  The most common pattern of PsA in patients with autoimmune ophthalmic disease is the oligoarticular form. 

1.Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955-9. Epub 2007/10/27. doi: ard.2007.075754


Disclosure:

S. Schwartzman,

Abbott Immunology Pharmaceuticals,

5,

Abbott Immunology Pharmaceuticals,

8,

Janssen Pharmaceutica Product, L.P.,

5,

Janssen Pharmaceutica Product, L.P.,

8,

Genentech and Biogen IDEC Inc.,

5,

Genentech and Biogen IDEC Inc.,

8,

ucb,

5,

ucb,

8,

Amgen,

8,

antares,

8,

Pfizer Inc,

5,

Paizer,

8;

A. Kolomeyer,
None;

D. Chu,

Xoma Corporation ,

5,

Sanofi-Aventis Pharmaceutical,

2,

Biogen Idec,

5,

Bausch & Lomb,

5,

alcon,

8,

Allergan,

2.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-spectrum-of-autoimmune-ophthalmic-manifestations-in-psoriatic-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.